Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Ionis Pharmaceuticals Inc shares valued at $477,900 were purchased by Hayden Michael R on May 01 ’25. At $31.86 per share, Hayden Michael R acquired 15,000 shares. The insider’s holdings grew to 50,219 shares worth approximately $2.15 million following the completion of this transaction.
Also, Birchler Brian sold 680 shares, netting a total of over 19,292 in proceeds. Following the sale of shares at $28.37 each, the insider now holds 56,660 shares.
Before that, Jenne Kyle had sold 3,016 shares from its account. In a trade valued at $85,534, the EVP, Chf GL Pdt Str Ofcr traded Ionis Pharmaceuticals Inc shares for $28.36 each. Upon closing the transaction, the insider’s holdings decreased to 3,016 shares, worth approximately $0.48 million.
As published in a research note from Barclays on July 01, 2025, Ionis Pharmaceuticals Inc [IONS] has been rated up from an Equal weight to an Overweight and the price target has been revised to $57. Analysts at H.C. Wainwright started covering the stock with ‘”a Buy”‘ outlook in a report released in early April. As of March 31, 2025, Redburn Atlantic has initiated its “Neutral” rating for IONS. Earlier on August 02, 2024, BMO Capital Markets downgraded its rating. Their new recommendation was “a Market perform” for IONS stock which previously was a “an Outperform”.
Analyzing IONS Stock Performance
On last trading session,, Ionis Pharmaceuticals Inc [NASDAQ: IONS] rose 3.60% to $42.83. The stock’s lowest price that day was $41.44, but it reached a high of $42.95 in the same session. During the last five days, there has been a surge of approximately 7.24%. Over the course of the year, Ionis Pharmaceuticals Inc shares have dropped approximately -7.07%. Shares of the company reached a 52-week high of $43.71 on 07/02/25 and a 52-week low of $23.95 on 04/09/25.
Support And Resistance Levels for Ionis Pharmaceuticals Inc (IONS)
According to the 24-hour chart, there is a support level at 41.86, which, if violated, would cause prices to drop to 40.90. In the upper region, resistance lies at 43.37. The next price resistance is at 43.92. RSI (Relative Strength Index) is 71.01 on the 14-day chart, showing overbought technical sentiment.
Is Ionis Pharmaceuticals Inc subject to short interest?
Stocks of Ionis Pharmaceuticals Inc saw a sharp steep in short interest on 2025-06-13 dropping by -1.04 million shares to 14.23 million. Data from Yahoo Finance shows that the short interest on 2025-05-15 was 15.27 million shares. A decline of -7.31% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 10.23 of the overall float, the days-to-cover ratio (short ratio) decline to 10.23.
Which companies own the most shares of Ionis Pharmaceuticals Inc (IONS)?
In terms of Ionis Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 55 in the next 12 months, up nearly 33.04% from the previous closing price of $41.34. Analysts anticipate Ionis Pharmaceuticals Inc stock to reach 77 by 2025, with the lowest price target being 28. In spite of this, 14 analysts ranked Ionis Pharmaceuticals Inc stock as Buy at the end of 2025. On July 24, 2024, Leerink Partners assigned a price target of “an Outperform” to the stock and upgraded coverage with a $62.
